|
Apr 11
|
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
|
|
Apr 10
|
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
|
|
Apr 10
|
PatientView Ranks Gilead "Best" at ESG
|
|
Apr 9
|
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
|
|
Apr 9
|
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
|
|
Apr 9
|
2 Top Dividend Stocks That Could Set You Up for Life
|
|
Apr 8
|
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections
|
|
Apr 7
|
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
|
|
Mar 14
|
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
|
|
Mar 13
|
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
|
|
Mar 13
|
GILD vs. VRTX: Which Stock Is the Better Value Option?
|
|
Mar 13
|
Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?
|
|
Mar 13
|
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
|
|
Mar 12
|
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
|
|
Mar 12
|
Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To
|
|
Mar 12
|
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
|
|
Mar 12
|
Gilead Presents New HIV Treatment And Cure Research Data
|
|
Mar 12
|
The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas
|
|
Mar 12
|
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
|
|
Mar 12
|
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
|